Kornimate/medical-research-clean huggingface dataset:
breast cancer ai imaging study

Conditions: Breast Cancer; Breast Cancer Screening

Summary: this study aims to develop a social health platform called mammochat (https://mammochat.com) that allows patients to share their real-world patient data to a trusted network for development of clinical intelligence to improve patient outcomes. therefore: 1. the investigator will establish a discourse social network where patients can anonymously and securely share their breast imaging and interact with other patients. 2. the investigator will use standardized questionnaires to understand the impact of use of the social network on outcomes related to breast cancer screening such as anxiety. 3. the investigator will assemble a crowdsourced, de-identified radiographic repository for training, testing, and validating ai models aimed at earlier and more accurate disease detection for breast cancer.

with over 40,000,000 mammograms run annually in the us, there are psychological consequences of breast cancer imaging that are well documented among patients such as stress and anxiety from largely false positive or indeterminant readings by radiologists. this ucf mammochat platform is one of the first projects that engages patients to donate their breast cancer imaging in an effort to reduce the psychological consequences of breast cancer imaging using social networks and artificial intelligence. this repository will be supported and maintained by the university of central florida college of medicine (ucf com) clinical and aerospace research team. these clinical research coordinators will operate the repository, including administering patients, imaging sites and transfers through an administrative panel.

Eligibility criteria:
inclusion criteria: * adults, ages 18 and older * had a radiographic breast cancer imaging test, either for screening or diagnosis of breast cancer, with either positive or negative results performed in a us institution. * have an email account with access to a reliable internet connection or smartphone exclusion criteria: * minors , ages under 18 * prisoners. given the repository design, prisoners are unlikely to participate and provide a consent * adults who are unable to provide consent.

Keywords: breast cancer artifical inteligence ai
long term evaluation of sevelamer hcl vs. calcium-based phosphate binder in the treatment of hyperphosphatemia in hemodialysis patients

Conditions: Hemodialysis; Hyperphosphatemia; Cardiovascular Events

Summary: the study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.


Eligibility criteria:
inclusion criteria: * males or females aged between 18-70 years old * subject with hyperphosphatemia (5.5 - 8.5 mg/dl) at both wk(-2) and wk0 * on stable tiw hemodialysis for 3 months or longer exclusion criteria: * patients with hypercalcemia (corrected serum calcium \> 10.5 mg/dl) * any of the following abnormalities: alt or ast \> 3x uln; ipth \> 1000 or \< 150 pg/ml * history of dysphagia or swallowing disorders * history of gi motility disorder or gi bleeding within 3 months prior to entry

Keywords: phosphate binder
follow-up of nafld patients with mri-pdff

Conditions: Diabetes Type 2; NAFLD

Summary: the liver is a key organ in metabolism and contributes to t2dm development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an important role in the pathogenesis of both nafld and t2dm.

this study aims to define * the effects of ptx, empagliflozin as an example of sglt-2 inhibitors and udca on liver biomarkers and liver steatosis in type 2 diabetic patients. * studying ptx, empagliflozin as an example of sglt-2 inhibitors and udca efficacy and safety as add-on therapy in type 2 diabetic patients.

Eligibility criteria:
inclusion criteria: * patients who are willing to participate in this study * adults aged ≥ 18 years old presented at the clinic with a confirmed diagnosis of t2dm who are on sulfonylurea for the last 6 months at least and diagnosed with nafld. exclusion criteria: * • patients who refused to participate in this trial * patients diagnosed with type 1 diabetes * previous history of alcohol intake * history of recurrent attacks of ketoacidosis in a diabetic patient * type 2 diabetic patient with kidney dysfunction (estimated egfr below 60ml/min/1.73m2 or crcl below 60ml/min) or on dialysis * previous history of taking medication that may alter either drug efficacy (eg, corticosteroids, oral contraceptives, and thiazide diuretics) * evidence of another liver disease (viral hepatitis, drug-induced liver disease, autoimmune hepatitis) * lactating/pregnant female or children ≤ 18 * any contraindication for empagliflozin including: 1. history of recurrent attacks of uti or genital infection in females 2. history of recurrent foot injuries or infections 3. type 2 diabetic patient with cv disease especially nyha classes iii/ iv 4. immunocompromised patients or with a history of inflammatory, immunological, or malignant diseases. * any contraindication for ptx including: 1. hypersensitivity to ptx 2. patients with peptic ulcer disease or tendency for bleeding * any contraindication for udca including: 1. hypersensitivity to udca 2. patients with biliary disease or hepatobiliary disease (ascites, jaundice) 3. patients with hepatic encephalopathy or gallstone pancreatitis
kids obesity prevention program - study (kop)

Conditions: Obesity; Child

Summary: obesity and its associated comorbidities are becoming a key and rapidly growing public health problem. the cause of obesity is an imbalance between energy intake and energy expenditure in favor of the former. childhood and adolescence are seen as critical time for its development. it is therefore crucial to provide both prevention and treatment actions already during childhood. the prevention and treatment weight-management programs in children focus on improving diet, eating behaviours, psychosocial aspects and increasing physical activity. one important basic requirement for any weight-management program is, that both children and their families are motivated and ready for change. video games, including exergames, serious games or combined approaches offer additional chances in the treatment and prevention of obesity by approaching children in their environment and motivating them to deal with life-style topics. the investigators developed a motion-controlled serious game for children aged between 9 and 12 years, addressing all the three core areas nutrition, physical activity, and psychosocial factors. in addition to the motion control, a tablet is used for knowledge-based and cognitive tasks. in comparison to other studies the nutrition part not only deals with the food pyramid but also with the energy density of foods and liquids and offers a self-reflexive diagnostic tool to analyse daily food intake. moreover, psychological aspects, especially stress and stress-coping strategies are addressed e.g. by relaxation-exercises. the game consists of two sessions, having each a duration of about 35 minutes. the aim of this study is to evaluate the program in a cluster-randomized controlled trial in a primary school setting in children aged 9 to 12 years. therefore, six 4th grade classes of the same school will be randomly allocated to an intervention and a control group. the intervention group will play the game within two weeks, whereas the control group will receive basic information. at baseline, two weeks after baseline and at four weeks follow-up, measurements will be performed. the primary outcome of the study is the gain of knowledge (nutrition, psychosocial aspects) measured by a self-constructed questionnaires tailored specifically for the serious game. secondary outcomes are the acceptance of the game, changes of nutrition behaviour, physical activity and intentions of the children to follow a healthy lifestyle, measured by mostly validated questionnaires.


Eligibility criteria:
inclusion criteria: * all children which belong to the 4th graders of a primary school exclusion criteria: * children with massive linguistic difficulties will be excluded (after study participation; due to ethical reasons we can not do this ahead)

Keywords: obesity child primary prevention serious game nutrition physical activity psychosocial stress knowledge diet
red cell distribution width,,nt-probnp and ctnt in acute myocardial infraction patient

Conditions: Myocardial Infarction

Summary: the study is to investigate the relationship of several parameters of complete blood count (cbc) including rdw with n-terminal pro-b-type natriuretic peptide (nt-probnp) and cardiac troponin t (ctnt) in a cohort of acute myocardial infarction (ami) patients.

patients and methods: * type of study: observational prospective study * place of study: sohag cardiology and gastroenterology center, department of cardiology and cardiac care unit. * ethical considerations: this research will be revised by the scientific ethical committee of sohag university hospital. consents will be taken from all patients. * study methods: * a prospective study on 30 patients diagnosed as acute myocardial infarction on which measurement of cbc, serum nt-probnp, and ctnt levels will be performed at the time of admission and by the time of discharge. * all patients included in the study will be subjected to: 1. full history: 1. personal history: e.g. age, sex and smoking. 2. family history of cardiac diseases 3. medical history of: hypertension, ischemic heart disease, prior coronary artery bypass grafting, prior percutaneous coronary intervention, prior stroke, prior atrial fibrillation, therapeutic history 2. detailed clinical examination 3. electrocardiogram 4. laboratory investigation: 1. routine investigation in the form of cbc including rdw 2. specific investigation which include nt-probnp and ctnt

Eligibility criteria:
inclusion criteria: * patients diagnosed as acute myocardial infarction and admitted to department of cardiology and cardiac care unit at sohag cardiology and gastroenterology center according to inclusion and exclution criteria exclusion criteria: patient with: * decompensated heart failure * pulmonary hypertention * acute pulmonary embolism * septic shock
comparison of nn1250 with insulin glargine in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in africa, asia, europe, and north america. the aim of this clinical trial is to compare the efficacy and safety of nn1250 (insulin degludec (ideg)) with insulin glargine (iglar) in subjects with type 2 diabetes currently treated with metformin alone or with metformin combined with an oral anti-diabetic drug (oad) qualifying for intensified treatment.


Eligibility criteria:
inclusion criteria: * insulin naïve subject (allowed are: previous short term insulin treatment up to 14 days; treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days) * current treatment: metformin monotherapy or metformin in any combination with insulin secretagogues (sulphonylurea (su) or glinide), dpp-4 inhibitor, alpha-glucosidase-inhibitor (acarbose) with unchanged dosing for at least three months prior to visit 1 with the minimum doses stated: -metformin: alone or in combination (including fixed combination) 1500 mg daily or maximum tolerated dose (at least 1000 mg daily) -insulin secretaguogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling -dpp-4 inhibitor: minimum half of the daily maximal dose according to local labelling -alpha-glucosidase-inhibitor (acarbose): minimum half of the daily maximal dose or maximum tolerated dose * hba1c 7.0-10.0 % (both inclusive) by central laboratory analysis * body mass index (bmi) below or equal to 45.0 kg/m\^2 exclusion criteria: * use within the last 3 months prior to visit 1 of: thiazoledinediones, exenatide or liraglutide * cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty * uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (hg) and/or diastolic blood pressure at least 100 mmhg) * pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements (for uk: adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system, or consistent use of barrier methods) * cancer and medical history of cancer hereof (except basal cell skin cancer or squamous cell skin cancer)
a study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (echo-204)

Conditions: B-cell Malignancies; Colorectal Cancer (CRC); Head and Neck Cancer; Lung Cancer; Lymphoma; Melanoma; Ovarian Cancer; Glioblastoma

Summary: this is a phase 1/2, open label study. phase 1 consists of 2 parts. part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (scchn) and non-small cell lung cancer (nsclc). phase 2 will include expansion cohorts in 7 tumor types, including melanoma, nsclc, scchn, colorectal cancer, ovarian cancer, glioblastoma and diffuse large b-cell lymphoma (dlbcl).


Eligibility criteria:
inclusion criteria: * male or female subjects, age 18 years or older * subjects with histologically or cytologically confirmed nsclc, mel (including i/o relapsed mel or i/o refractory mel), crc, scchn, ovarian cancer, recurrent b cell nhl or hl, or glioblastoma * presence of measurable disease by recist v1.1 for solid tumors or cheson criteria for b cell nhl (including dlbcl) or hl. for subjects with glioblastoma, presence of measurable disease is not required. * eastern cooperative oncology group (ecog) performance status 0 to 1 * fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of the most recent prior chemotherapy regimen) are required for all cohorts except glioblastoma exclusion criteria: * laboratory and medical history parameters not within protocol-defined range * currently pregnant or breastfeeding * subjects who have received prior immune checkpoint inhibitors or an ido inhibitor (except select phase 2 cohorts evaluating i/o relapsed or i/o refractory mel). subjects who have received experimental vaccines or other immune therapies should be discussed with the medical monitor to confirm eligibility * untreated central nervous system (cns) metastases or cns metastases that have progressed * subjects with any active or inactive autoimmune process * evidence of interstitial lung disease or active, noninfectious pneumonitis * subjects with any active or inactive autoimmune process * ocular mel
pancreas volume and diabetes status following pancreatectomy

Conditions: Pancreatic Neoplasms

Summary: this study will enroll 100 patients scheduled to undergo a pancreatectomy. the primary objective is to develop a scoring system using pancreatic volume measured by ct scan and intraoperative measurements of the pancreas parenchyma to predict the onset of diabetes mellitus after a pancreatectomy. the investigators will also monitor patients with pre-existing diabetes to see if their diabetes worsens or improves.

the primary objective is to develop a scoring system using pancreatic volume measured by ct scan and intraoperative measurements of the pancreas parenchyma to predict the onset of diabetes mellitus after a pancreatectomy. the investigators will also monitor patients with pre-existing diabetes to see if their diabetes worsens or improves. patients will be followed up to one year to track their diabetes status, postoperative outcomes and quality of life.

Eligibility criteria:
inclusion criteria: * all patients undergoing pancreatectomy at our institution (e.g., pancreaticoduodenectomy, distal pancreatectomy, distal pancreatectomy and splenectomy, central pancreatectomy). exclusion criteria: * all patients who are on steroids or other medications whose potential side effects include development of diabetes mellitus or elevated blood glucose. * pregnant or nursing women. * patients with uncontrolled diabetes (hba1c \>8%).
evaluation of long-term clinical and radiographic outcomes of radio-capitellar prostheses

Conditions: Radiocapitellar Dislocation

Summary: the aim of this study is to collect clinical and radiographic data from the case histories of patients surgically treated for radio-capitellar fracture and undergoing prosthetic replacement with a modular metal radio-capitellar prosthesis with smooth stem at the shoulder-elbow department of the rizzoli orthopaedic institute, in order to evaluate the clinical and radiographic results at least 10 years after surgery.

the aim of the study is to collect clinical and radiographic data from the case history of patients (about 30 cases) surgically treated from 2003 to 2011 at the shoulder-elbow department of the rizzoli orthopaedic institute for radio-capitellar fracture with prosthetic replacement with a modular metal radio-capitellar prosthesis with smooth stem in order to evaluate the clinical and radiographic results at least 10 years after treatment. patients will be contacted to perform a clinical examination and radiographic control at the rizzoli orthopaedic institute. this is an interventional study with clinical and radiographic evaluation, at fu of at least 10 years, of patients treated surgically with prosthetic replacement for radio-capitellar fracture at the shoulder-elbow department of the rizzoli orthopaedic institute.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age at the time of radial capitate implantation surgery 2. males and females 3. patients surgically treated for radial capitellum fracture undergoing prosthetic replacement with smooth-stemmed modular metal radial capitellum prosthesis at the shoulder-elbow department of the rizzoli orthopaedic institute from 2003 to 2011. exclusion criteria: 1. \< 18 years old at the time of surgery 2. patients treated with radial capitellum prosthesis implantation in fracture outcomes (e.g., secondary instability) 3. patients who at the time of telephone contact have contraindications to the execution of radiographic examination 4. all available patients will be invited to perform the clinical examination and radiographic examination. if some patients are unable to undergo radiography due to possible contraindications, they will still be seen to collect the primary clinical outcome.

Keywords: radio-capitellar fracture interventional study radiographic assessment radio-capitellar prosthetic arthroplasty long term clinical results long term radiographic results radio-capitellar prosthesis radiographic results clinical results
a cohort study for the following up of conization

Conditions: Precancerous Lesions; Conization; High Grade Intraepithelial Neoplasia; Uterine Cervical Cancer; Fertility; Pregnancy; Human Papillomavirus Infection

Summary: this study is to investigate the oncologic and obstetric outcomes in patients with conization for uterine cervical lesions from january 1, 2000 to january 1, 2019 in peking union medical college hospital. the primary objectives consist of following: 1. the cumulative incidences of precancerous lesions and cancers of lower genital tract in patients who accepted conization for high grade intraepithelial neoplasia (hsil), carcinoma in situ and stage ia1 cancer (figo 2009) 2. the cumulative pregnancy rates in patients sparing the fertility the secondary objectives consist of following: 1. the effects of surgical protocols (modified sturmdorf method and "8" figure suture) and energy equipment (cold knife and monopolar electrical cautery) on the oncologic and obstetric outcomes, and on the histological components. 2. a full description of histological components of the conization specimens 3. the cytological and virus outcomes after conization, based on the thin prep liquid-based cytology test (tct) and high-risk human papillomavirus (hpv) testing


Eligibility criteria:
inclusion criteria: * accepting conization in the study center * aged 18 years or older exclusion criteria: * not meeting any of the inclusion criteria
zambia sivet mmr tdap-ipv

Conditions: High Risk for HIV

Summary: participants will receive vaccination for measles, mumps, and rubella (mmr) and tetanus, diphtheria, pertussis, and inactivated polio (tdap-ipv). the study schedule design is to simulate a vaccine efficacy trial to see if single women can participate in studies that mimic actual hiv vaccine studies.

this study will evaluate if women at high risk for hiv infection residing in lusaka, zambia and ndola, zambia are willing to participate and can be retained in future hiv vaccine trials. 150 women will be enrolled that are either sex workers or single women that were identified at infant vaccination clinics (at risk due to a recent pregnancy indicating unprotected sexual contact outside of marriage or cohabitation). two licensed vaccines will be administered as proxies for hiv vaccine administration. the clinic and laboratory procedures will simulate hiv vaccine trial procedures and will therefore inform recruitment and retention strategies and hiv incidence among high risk women in future hiv vaccine trials.

Eligibility criteria:
inclusion criteria: * at high risk of hiv, defined by occupation (female sex workers) or recent delivery (single mothers) * planning to stay in lusaka or ndola for at least 12 months * willing to undergo hiv testing, counseling and receive hiv test results able and willing to provide adequate locator information for tracking purposes, and willing to be contacted by the study staff * willing and able to provide adequate locator information and willing to be contacted by phone if available or home visit by study staff. * willing to answer questions on hiv risk factors, and if infected, questions related to the route and timing of exposure * willing and able to return for follow-up visits * willing and able to provide informed consent * willing to undergo pregnancy testing and use an injectable, implant or intrauterine device (iud) from screening until four months after the last vaccination during the study exclusion criteria: * hiv-1/2 infection * pregnant or intending to become pregnant during the study * history of severe allergic reaction to any substance including eggs, gelatin, and neomycin * any clinically significant acute illness or chronic medical condition that is considered progressive, or in the opinion of the investigator, makes the volunteer unsuitable for participation in the study * immunosuppressive therapy * women who opt out of hiv counseling and testing services provided by the clinic * women who have any condition that in the opinion of the investigator or designee, would preclude provision of informed consent, or otherwise interfere with achieving the study objectives * participation in another clinical trial unless approved by the principal investigator and the international aids vaccine initiative (iavi) * recent receipt of an investigational blood product or vaccine * failure of assessment of understanding

Keywords: aids immunology public health female sex workers single mothers